GlassScriptPhysician profile
Bernadette Rojvanit
NPI 1104487735
$2,922.07
in general payments reported to CMS, 2019-2025
26 companies · $720 in 2025
The $720 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $465 · 2023: $838 · 2024: $640 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $389.68 | 2023-2024 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $344.42 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $284.97 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $250.96 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $212.85 | 2022-2025 | Ozempic, Wegovy |
| Edwards Lifesciences Corporation | $204.58 | 2022-2025 | Pascal |
| Actelion Pharmaceuticals US, INC. | $165.61 | 2022-2025 | Opsumit, Uptravi |
| Amgen INC. | $163.63 | 2021-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $157.89 | 2023-2024 | Inpefa |
| Medtronic, INC. | $128.99 | 2025 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $115.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.47 | 2022-2025 | Jardiance |
| Angiodynamics, INC. | $68.85 | 2022-2024 | Auryon Laser System 100-120 Vac |
| Biotronik INC. | $65.71 | 2023 | Oscar |
| Alnylam Pharmaceuticals INC. | $41.10 | 2022-2024 | Amvuttra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.66 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.93 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $27.57 | 2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $22.30 | 2025 | Nexletol |
| Liquidia Technologies, INC. | $21.32 | 2025 | Yutrepia |
| Amryt Pharma Holdings LTD | $20.49 | 2022 | |
| Scpharmaceuticals INC. | $19.85 | 2023 | |
| Cardiac Dimensions, INC. | $17.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.58 | 2025 | |
| Kestra Medical Technology Services, INC. | $16.04 | 2024 | Assure Wcd |
| Pfizer INC. | $14.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Rojvanit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.